VMP方案治疗多发性骨髓瘤的临床观察
摘要
多发性骨髓瘤（MM）是一种浆细胞克隆性增生的恶性血液系统肿瘤,目前仍为一种不能治愈的疾病。传统的化疗方案仅能保持患者的中位生存期为3～5年,且复发率较高。笔者采用VMP化疗方案治疗复发、难治的MM患者5例,取得了良好疗效。现报道如下。
出处
《临床合理用药杂志》
2011年第2期78-79,共2页
Chinese Journal of Clinical Rational Drug Use
参考文献4
-
1Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents [J]. Clin Cancer Res,2003,9 : 1136 - 1144.
-
2Dimopoulos MA, Richardson PG, Schlag R, et al. VMP( Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment:cohort analysis of the phase Ⅲ VISTA study[J]. J Clin Oncol,2009,27(36) :6086-6093.
-
3Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone [ J ]. Blood,2010,116 ( 19 ) :3743 - 3750.
-
4高珊,付蓉,关晶,王婷,邵宗鸿.VDZ方案治疗多发性骨髓瘤疗效观察[J].肿瘤,2009,29(6):585-588. 被引量：5
二级参考文献10
-
1BLADE J, SAMSON D, REECE D, et al. Criteria for evaluating disease response and progression in patients with multiplemyeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. European Group for Blood and Marrow Transplant [ J ]. Br J Haematol, 1998,102 (5) : 1115-1123.
-
2FIELD-SMITH A, MORGAN G J, DAVIES F E. Bortezomib (Veleade^TM) in the treatment of multiple myeloma[J]. Ther Clin Risk Manag, 2006, 2 ( 3 ) :271-279.
-
3ROODMAN G D. Bone building with bortezomib [ J ]. J Clin Invest, 2008, 118(2) :462-464.
-
4SMITH M R. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence [ J ]. Cancer Treat Rev, 2005, 31(3) :19-25.
-
5YEH H S, BERENSON J R. Treatment for myeloma bone disease [ J ]. Clin Cancer Res,2006,12 (20) :6279-6284.
-
6JAGANNATH S, BRIAN D, WOLF JL, et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma [J]. Blood, 2004,104 : Abstract 333.
-
7RICHARDSON P G, CHANAN-KHAN A, SCHLOSSMAN R L, et al. Phase Ⅱ trial of single agent bortezomib in patients with previously untreated multiple myeloma [ J ]. Blood, 2004, 104 : Abstract 336.
-
8WU K L, VAN WIERINGEN W, VELLENGA E, et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice[ J], Haematologica, 2005, 90 (7) :996-997.
-
9黄红铭,周莉莉,侯健.硼替佐米对多发性骨髓瘤患者破骨细胞生成的影响及机制研究[J].肿瘤,2008,28(11):964-967. 被引量：6
-
10李勇华,侯健.多发性骨髓瘤治疗中值得关注的几个问题[J].肿瘤,2008,28(11):1008-1011. 被引量：5
共引文献4
-
1张国栋,李梅君.小剂量沙利度胺联合地塞米松治疗初诊多发性骨髓瘤的临床研究[J].肿瘤,2009,29(11):1090-1093. 被引量：2
-
2宋斌,万楚成,李章志,陈雁.艾迪注射液联合VAD方案治疗老年多发性骨髓瘤的临床研究[J].中国医药导报,2012,9(7):69-70. 被引量：7
-
3刘倩平,邹三鹏,章志福.沙利度胺联合地塞米松治疗初治多发性骨髓瘤的疗效和安全性[J].中国社区医师（医学专业）,2012,14(12):157-158. 被引量：4
-
4宋斌,陈雁.低剂量沙利度胺联合化疗方案治疗老年多发性骨髓瘤28例[J].重庆医学,2014,43(3):341-343. 被引量：24
